Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

1.120 -0.190 (-14.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hookipa Pharma Inc

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Sidoti's November Micro-Cap Virtual Conference
Via ACCESSWIRE
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma (NASDAQ: HOOK) Enters into Collaboration Deal with Roche to Develop HB-700 For KRAS-Mutated Cancers
HOOKIPA Pharma, Inc. (NASDAQ: HOOK) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.